No profile data available.
Lexaria Bioscience Corp. (LEXX) is a healthcare company in the pharmaceutical administration systems industry, based in Kelowna, Canada, with about 7 full-time employees.
It reported revenue of $705,923 for fiscal year 2025, up 52.0% from fiscal year 2024, and net income of -$11.90 million. In Q3 2026 (the quarter ended May 31, 2026) revenue was $0, down 100.0% from a year before. Its largest business segment, Intellectual Property Licensing, brought in 99% of segment revenue in fiscal year 2025. Its market capitalization was $6.99 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended August 31, 2025; market data as of October 9, 2026.
Lexaria Bioscience Corp. operates as a biotechnology company.
Lexaria Bioscience reported $705,923 in revenue for fiscal year 2025, up 52.0% from $464,278 in fiscal year 2024. In Q3 2026 revenue was $0.
Intellectual Property Licensing, with $696,000 or 99% of segment revenue in fiscal year 2025. Next: B2B Product (1%).
$6.99 million as of October 9, 2026.
Listed companies of a similar size in the same industry (pharmaceutical administration systems) include Roivant Sciences Ltd. (ROIV), Rani Therapeutics Holdings, Inc. (RANI), Xenetic Biosciences, Inc. (XBIO), Skinvisible, Inc. (SKVI).